cilostazol has been researched along with Sensitivity and Specificity in 11 studies
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats." | 7.71 | The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus. ( Ahn, YB; Cha, BY; Chang, SA; Han, JH; Kang, MI; Kang, SK; Lee, JM; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH, 2001) |
| "These findings suggested that cilostazol may improve insulin resistance in STZ-induced non-insulin dependent diabetic rats." | 3.71 | The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus. ( Ahn, YB; Cha, BY; Chang, SA; Han, JH; Kang, MI; Kang, SK; Lee, JM; Lee, KW; Son, HS; Son, HY; Song, KH; Yoo, SJ; Yoon, KH, 2001) |
| "Cilostazol has been shown to be effective for prevention and treatment of cerebral infarction." | 1.38 | Platelet aggregometry in the presence of PGE(1) provides a reliable method for cilostazol monitoring. ( Fukasawa, I; Inoue, O; Kanemaru, K; Kimura, Y; Kinouchi, H; Ohta, M; Ozaki, Y; Satoh, K; Yoda, S, 2012) |
| " The validated method has been successfully used to analyze human plasma samples for application in pharmacokinetics, bioavailability or bioequivalence studies." | 1.33 | Simultaneous quantification of cilostazol and its primary metabolite 3,4-dehydrocilostazol in human plasma by rapid liquid chromatography/tandem mass spectrometry. ( Datla, PV; Kandikere, VN; Mudigonda, K; Nirogi, RV; Shrivasthava, W; Shukla, M; Yerramilli, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Shen, Y | 1 |
| Jiang, B | 1 |
| Hu, X | 1 |
| Chen, J | 1 |
| Xu, Y | 1 |
| Ruan, Z | 1 |
| Yang, D | 1 |
| Lou, H | 1 |
| Yamanouchi, J | 1 |
| Hato, T | 1 |
| Niiya, T | 1 |
| Nakagawa, K | 1 |
| Kumon, Y | 1 |
| Fujiwara, H | 1 |
| Yakushijin, Y | 1 |
| Yasukawa, M | 1 |
| Satoh, K | 1 |
| Fukasawa, I | 1 |
| Kanemaru, K | 1 |
| Yoda, S | 1 |
| Kimura, Y | 1 |
| Inoue, O | 1 |
| Ohta, M | 1 |
| Kinouchi, H | 1 |
| Ozaki, Y | 1 |
| Kwon, SU | 1 |
| Cho, YJ | 1 |
| Koo, JS | 1 |
| Bae, HJ | 1 |
| Lee, YS | 1 |
| Hong, KS | 1 |
| Lee, JH | 1 |
| Kim, JS | 1 |
| Nirogi, RV | 1 |
| Kandikere, VN | 1 |
| Shukla, M | 1 |
| Mudigonda, K | 1 |
| Shrivasthava, W | 1 |
| Datla, PV | 1 |
| Yerramilli, A | 1 |
| Fayed, AS | 1 |
| Shehata, MA | 1 |
| Ashour, A | 1 |
| Hassan, NY | 1 |
| Weshahy, SA | 1 |
| Tata, PN | 3 |
| Fu, CH | 2 |
| Browder, NJ | 1 |
| Chow, PC | 1 |
| Bramer, SL | 3 |
| Fu, CJ | 1 |
| Okada, K | 1 |
| Akiyama, H | 1 |
| Chang, SA | 1 |
| Cha, BY | 1 |
| Yoo, SJ | 1 |
| Ahn, YB | 1 |
| Song, KH | 1 |
| Han, JH | 1 |
| Lee, JM | 1 |
| Son, HS | 1 |
| Yoon, KH | 1 |
| Kang, MI | 1 |
| Lee, KW | 1 |
| Son, HY | 1 |
| Kang, SK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for cilostazol and Sensitivity and Specificity
| Article | Year |
|---|---|
Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis.
Topics: Aged; Angiography; Arteries; Aspirin; Brain; Cilostazol; Constriction, Pathologic; Disease Progressi | 2005 |
10 other studies available for cilostazol and Sensitivity and Specificity
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
A new simple method for quantification of cilostazol and its active metabolite in human plasma by LC-MS/MS: Application to pharmacokinetics of cilostazol associated with CYP genotypes in healthy Chinese population.
Topics: China; Chromatography, Liquid; Cilostazol; Cytochrome P-450 Enzyme System; Genotype; Humans; Linear | 2021 |
Vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay for platelet response to cilostazol.
Topics: Blood Platelets; Blotting, Western; Cell Adhesion Molecules; Cilostazol; Clinical Laboratory Techniq | 2011 |
Platelet aggregometry in the presence of PGE(1) provides a reliable method for cilostazol monitoring.
Topics: Aged; Alprostadil; Arachidonic Acid; Blood Platelets; Cilostazol; Drug Monitoring; Female; Humans; M | 2012 |
Simultaneous quantification of cilostazol and its primary metabolite 3,4-dehydrocilostazol in human plasma by rapid liquid chromatography/tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Cilostazol; Humans; Molecular Structure; Reproducibility of Re | 2006 |
Validated stability-indicating methods for determination of cilostazol in the presence of its degradation products according to the ICH guidelines.
Topics: Calibration; Chromatography, High Pressure Liquid; Cilostazol; Drug Stability; Guidelines as Topic; | 2007 |
The quantitative determination of cilostazol and its four metabolites in human liver microsomal incubation mixtures by high-performance liquid chromatography.
Topics: Acetonitriles; Calibration; Chromatography, High Pressure Liquid; Cilostazol; Drug Stability; Humans | 1998 |
Simultaneous quantitative determination of cilostazol and its metabolites in human plasma by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Cilostazol; Humans; Reference Standards; Reproducibility of Re | 1999 |
Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Cilostazol; Humans; Reference Standards; Reproducibility of Re | 2001 |
The effect of cilostazol on glucose tolerance and insulin resistance in a rat model of non-insulin dependent diabetes mellitus.
Topics: Animals; Animals, Newborn; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Disease Models, Ani | 2001 |